£0.66
0.60%
London, Oct 05, 04:35 pm BST. Closed.
ISIN
GB00BL6NGV24
Symbol
DOCS

Dr Martens Stock price

£0.66
-0.05 7.02% 1M
+0.03 5.35% 6M
-0.08 10.56% YTD
-0.23 25.50% 1Y
-0.57 46.31% 3Y
-2.57 79.50% 5Y
-3.18 82.78% 10Y
-3.18 82.78% 20Y
London, Closing price Mon, Oct 05 2026
-0.00 0.60%
ISIN
GB00BL6NGV24
Symbol
DOCS

AI Insights on Dr Martens Insights AI Insights on Dr Martens

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Dr Martens a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
£642.3m
Enterprise Value
£853.4m
Net debt
£211.1m
Cash
£180.3m
Shares outstanding
956.6m
Valuation
P/E
22.2
P/S | estimate
0.8 | 0.8
EV/Sales | estimate
1.1 | 1.1
EV/FCF | ex SBC
6.5 | 6.8
P/B
1.8
Dividends
DPS
£0.03
Yield 1Y | 5Y
3.8% | 2.2%
Growth 1Y | 5Y
38.6% | -
Payout 1Y | 3Y
127.5% | 113.7%
Increased
1 Year
Financials
Revenue | estimate
£764.9m | £789.3m
EBITDA
£147.7m
EBIT
£79.3m
Net Income
£23.8m
Free Cash Flow | ex SBC
£130.8m | £125.6m
Growth
Revenue | estimate
-2.9% | 3.2%
EBITDA
3.7%
EBIT
13.4%
Net Income
428.9%
Free Cash Flow
-26.4%
Margin
Gross
66.2%
EBITDA
19.3%
EBIT
10.4%
Net
3.1%
Free Cash Flow | ex SBC
17.1% | 16.4%
Financial Health
Equity Ratio
41.2%
Return on Equity
6.6%
ROCE
11.1%
ROIC
10.7%
Debt/Equity
1.1
Share-Based Compensation & Dilution
SBC | % of Revenue
£5.2m | 0.7%
SBC as % of FCF
4.0%
SBC Growth 1Y
-27.8%
Share Count Growth 1Y
-0.7%
Shareholder Yield
4.6%
More
EPS
£0.0
FCF per Share
£0.1
Short interest
4,543.0%
Employees
2k
Rev per Employee
£320.0k

Dr Martens Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Dr Martens forecast:

6x Buy
60%
4x Hold
40%

Analyst Opinions

10 Analysts have issued a Dr Martens forecast:

Buy
60%
Hold
40%

Dr Martens Events

Past Events
MAY
19
Q4 2026 Earnings Call
5 months ago
JAN
27
Q3 2026 Earnings Call
8 months ago
NOV
20
Q2 2026 Earnings Call
11 months ago

Financial data from Dr Martens

Mar '26
+/-
%
765 765
3% 3%
100%
- Direct Costs 259 259
6% 6%
34%
506 506
1% 1%
66%
- Selling and Administrative Expenses 333 333
10% 10%
44%
- Research and Development Expense - -
-
-
148 148
4% 4%
19%
- Depreciation and Amortization 68 68
6% 6%
9%
EBIT (Operating Income) EBIT 79 79
13% 13%
10%
Net Profit 24 24
429% 429%
3%

In millions GBP.

Don't miss a Thing! We will send you all news about Dr Martens directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Dr. Martens Plc engages in the manufacture and sale of footwear products. The firm offers boots, shoes, sandals, shoe care products, laces, and socks. It operates through the following geographical segments: EMEA, Americas, and APAC. The company was founded by Klaus Maertens in 1945 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Mr. Nwokorie
Employees 2,377
Founded 1945
Website www.drmartensplc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today